Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024
Retrieved on:
Monday, April 8, 2024
Biotechnology, Men, Health, Consumer, Other Health, Pharmaceutical, Surgery, Other Science, Research, Medical Devices, Science, Women, Seniors, Clinical Trials, Week, Sciatica, LDH, Incidence, Ferring Pharmaceuticals, Patient, Spinal disc herniation, Șaeș, University, ESI, Quality of life, Manager, University of Illinois Urbana-Champaign, Society, Back pain, LSM, Pain, SAE
"Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."
Key Points:
- "Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."
- An analysis assessing current treatment patterns and gaps in clinical management of patients with newly diagnosed LDH was also presented.
- The analysis reviewed medical claims data of more than a million U.S. patients over a four-year period.
- Among patients who received more than one ESI, one in five (22.4%) underwent surgery with 14.2% of those patients receiving repeated surgeries.